A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Previously Treated Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
Sponsor: |
Zeno Pharmaceuticals |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS0192 |
U.S. Govt. ID: |
NCT03560531 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This research study involves receiving an experimental drug referred to as ZN-c5. This is the first study in humans using ZN-c5. The purpose of this research study is to test the safety of ZN-c5 at different dose levels. This study is designed to find out what effects, good and/or bad, ZN-c5 has on participants with breast cancer. Participants in both parts of the study may also be assigned to receive ZN-c5 alone, or ZN-c5 in addition to an FDA-approved medication for breast cancer called palbociclib (IBRANCE, Pfizer Inc.).
This study is closed
Investigator
Katherine Crew, MD
Are you 18 years or older? |
Yes |
No |
Have you been diagnosed with Breast cancer? |
Yes |
No |
Have you had no more than 2 prior treatments for Breast Cancer? |
Yes |
No |
Are you willing to undergo additional biopsies? |
Yes |
No |